Akari Therapeutics PLC - American Depositary Shares (AKTX) closed at $6.71 on November 19, 2026, up 0.9% from the previous close, on volume of 9,806 shares (30-day average 42,380).
Data as of November 19, 2026.
Akari: Buy Rating Reiterated as AKTX-101 Advances Toward Phase 1; $27 Price Target Unchanged
TipRanks (Mon, 16-Nov 6:55 AM ET)
Globe Newswire (Thu, 12-Nov 4:05 PM ET)
Globe Newswire (Wed, 11-Nov 8:44 AM ET)
Globe Newswire (Fri, 30-Oct 9:05 AM ET)
Globe Newswire (Thu, 15-Oct 9:20 AM ET)
AKTX Names Vatnak Vat-Ho as CBO as It Pushes AKTX-101 Toward a Mid-2027 First-in-Human Goal
Market Chameleon (Wed, 14-Oct 7:16 AM ET)
Globe Newswire (Tue, 13-Oct 9:01 AM ET)
Globe Newswire (Thu, 1-Oct 8:25 AM ET)
Globe Newswire (Tue, 8-Sep 9:15 AM ET)
Akari Therapeutics Participates in the Virtual Investor "Why Now" On-Demand Conference
Globe Newswire (Thu, 27-Aug 9:01 AM ET)
Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) built around novel, proprietary payloads utilizing powerful biology to attack cancer. Its payload, PH1, targets RNA splicing by modulating the spliceosome, a complex machinery in the cell that converts pre-RNA into spliced RNA for translation into vital proteins for cell survival and growth. Its product pipeline is AKTX-101, which targets the Trop2 receptor on cancer cells and, with a proprietary linker, enables it to deliver its novel PH1 payload directly into the tumor with minimal off-target effects. and AKTX-102, an ADC candidate targeting CEACAM5 (Carcinoembryonic Antigen-related Cell Adhesion Molecule-5), a well-validated tumor antigen expressed across multiple solid tumors.
Akari Therapeutics PLC - American Depositary Shares trades on the NASDAQ stock market under the symbol AKTX.
As of November 19, 2026, AKTX stock price climbed to $6.71 with 9,806 million shares trading.
AKTX has a beta of 3.14, meaning it tends to be more sensitive to market movements. AKTX has a correlation of 0.03 to the broad based SPY ETF.
AKTX has a market cap of $15.33 million. This is considered a Sub-Micro Cap stock.
In the last 3 years, AKTX traded as high as $176.00 and as low as $3.02.
AKTX has underperformed the market in the last year with a price return of -68.4% while the SPY ETF gained +9.6%. AKTX has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -15.1% and -27.8%, respectively, while the SPY returned -6.5% and -6.6%, respectively.
AKTX support price is $5.90 and resistance is $7.40 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that AKTX shares will trade within this expected range on the day.